Felpreva

Country: European Union

Language: Icelandic

Source: EMA (European Medicines Agency)

Active ingredient:

emodepside, praziquantel, Tigolaner

Available from:

Vétoquinol SA

ATC code:

QP52AA51

INN (International Name):

emodepside, praziquantel, tigolaner

Therapeutic group:

Kettir

Therapeutic area:

Ormalyfjum

Therapeutic indications:

For cats with, or at risk from, mixed parasitic infestations. The veterinary medicinal product is exclusively indicated when ectoparasites, cestodes and nematodes are targeted at the same time.

Authorization status:

Leyfilegt

Authorization date:

2021-11-11

Patient Information leaflet

                                18
B. FYLGISEÐILL
19
FYLGISEÐILL:
FELPREVA BLETTUNARLAUSN FYRIR LITLA KETTI (1,0 - 2,5 KG)
FELPREVA BLETTUNARLAUSN FYRIR MEÐALSTÓRA KETTI (> 2,5 – 5,0 KG)
FELPREVA BLETTUNARLAUSN FYRIR STÓRA KETTI (> 5,0 – 8,0 KG)
1.
HEITI OG HEIMILISFANG MARKAÐSLEYFISHAFA OG ÞESS FRAMLEIÐANDA
SEM BER ÁBYRGÐ Á LOKASAMÞYKKT, EF ANNAR
Markaðsleyfishafi og framleiðandi sem ber ábyrgð á lokasamþykkt:
Vetoquinol S.A.
Magny-Vernois
70200 Lure
Frakkland
2.
HEITI DÝRALYFS
Felpreva blettunarlausn fyrir litla ketti (1,0 - 2,5 kg)
Felpreva blettunarlausn fyrir meðalstóra ketti (> 2,5 - 5,0 kg)
Felpreva blettunarlausn fyrir stóra ketti (> 5,0 – 8,0 kg)
tígólaner/emódepsíð/prasikvantel
3.
VIRK(T) INNIHALDSEFNI OG ÖNNUR INNIHALDSEFNI
Hvert blettunaráhald inniheldur:
FELPREVA BLETTUNARLAUSN
RÚMMÁL
STAKSKAMMTS
[ML]
TÍGÓLANER
[MG]
EMÓDEPSÍÐ
[MG]
PRAZIKVANTEL
[MG]
fyrir litla ketti (1,0 - 2,5 kg)
0,37
36,22
7,53
30,12
fyrir meðalstóra ketti (> 2,5 –
5,0 kg)
0,74
72,45
15,06
60,24
fyrir stóra ketti (> 5,0 –
8,0 kg)
1,18
115,52
24,01
96,05
HJÁLPAREFNI: 2,63 mg/ml bútýlhýdroxýanísól (E320) og 1,10 mg/ml
bútýlhýdroxýtólúenl (E321) sem
andoxunarefni.
Blettunarlausn.
Tær gul til rauð lausn.
Litabreytingar geta komið fram við geymslu. Þetta hefur ekki áhrif
á gæði lyfsins.
4.
ÁBENDING(AR)
Handa köttum sem eru með eða eru í hættu á að fá blandaða
sníkjudýrasýkingu /-smit. Dýralyfið er
eingöngu ætlað til notkunar þegar veita á meðferð við
útsníklum, bandormum og þráðormum
samtímis.
Óværa

Til meðferðar við flóm (_Ctenocephalides felis_) og mítlum
(_Ixodes ricinus, Ixodes holocyclus_)
hjá köttum til tafarlausrar og viðvarandi drepandi verkunar í 13
vikur.

Dýralyfið má nota sem hluta af meðferðaráætlun til að ná
stjórn á ofnæmishúðbólgum vegna
flóabits (FAD).
20

Til meðhöndlunar við vægum til miðlungsvægum maurakláða (af
völdum _Notoedres cati_).

Til meðhöndlunar sýkinga af völdum eyrnamaura (_Otodectes
cy
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
VIÐAUKI I
SAMANTEKT Á EIGINLEIKUM LYFS
2
1.
HEITI DÝRALYFS
Felpreva blettunarlausn fyrir litla ketti (1,0 - 2,5 kg)
Felpreva blettunarlausn fyrir meðalstóra ketti (> 2,5 - 5,0 kg)
Felpreva blettunarlausn fyrir stóra ketti (> 5,0 – 8,0 kg)
2.
INNIHALDSLÝSING
VIRK INNIHALDSEFNI:
Hvert blettunaráhald inniheldur:
RÚMMÁL
STAKSKAMMTS
[ML]
TÍGÓLANER
EMÓDEPSÍÐ
PRAZIKVANTEL
Felpreva fyrir litla ketti
(1,0 - 2,5 kg)
0,37 ml
36,22 mg
7,53 mg
30,12 mg
Felpreva fyrir meðalstóra ketti
(> 2,5 – 5,0 kg)
0,74 ml
72,45 mg
15,06 mg
60,24 mg
Felpreva fyrir stóra ketti
(> 5 –8,0 kg)
1,18 ml
115,52 mg
24,01 mg
96,05 mg
HJÁLPAREFNI:
2,63 mg/ml bútýlhýdroxýanísól (E320) og 1,10 mg/ml
bútýlhýdroxýtólúen (E321) sem andoxunarefni.
Sjá lista yfir öll hjálparefni í kafla 6.1.
3.
LYFJAFORM
Blettunarlausn.
Tær gul til rauð lausn.
Litabreytingar geta komið fram við geymslu. Þetta hefur ekki áhrif
á gæði lyfsins.
4.
KLÍNÍSKAR UPPLÝSINGAR
4.1
DÝRATEGUNDIR
Kettir.
4.2
ÁBENDINGAR FYRIR TILGREINDAR DÝRATEGUNDIR
Handa köttum sem eru með eða eru í hættu á að fá blandað
sníkjudýrasmit/-sýkingu. Dýralyfið er
eingöngu ætlað til notkunar þegar veita á meðferð við
útsníklum, bandormum og þráðormum
samtímis.
Óværa

Til meðferðar við flóm (_Ctenocephalides felis_) og mítlum
(_Ixodes ricinus, Ixodes holocyclus_) hjá
köttum til tafarlausrar og viðvarandi drepandi verkunar í 13 vikur.

Dýralyfið má nota sem hluta af meðferðaráætlun til að ná
stjórn á ofnæmishúðbólgum vegna
flóabits (FAD).
3

Til meðhöndlunar við vægum til miðlungsvægum maurakláða
(_Notoedres cati_).

Til meðhöndlunar sýkinga af völdum eyrnamaura (_Otodectes
cynotis_)
Þráðormar í meltingarfærum (þráðormar)
Til meðhöndlunar sýkinga af völdum:

_Toxocara cati _(fullþroska fullorðnir, ófullþroska fullorðnir,
L4 og L3)

_Toxascaris leonina_ (fullþroska fullorðnir, ófullþroska
fullorðnir og L4)

_Ancylostoma tubaeforme_ (fullþroska fu
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 09-03-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 09-03-2022
Public Assessment Report Public Assessment Report Bulgarian 09-03-2022
Patient Information leaflet Patient Information leaflet Spanish 09-03-2022
Public Assessment Report Public Assessment Report Spanish 09-03-2022
Patient Information leaflet Patient Information leaflet Czech 09-03-2022
Public Assessment Report Public Assessment Report Czech 09-03-2022
Patient Information leaflet Patient Information leaflet Danish 09-03-2022
Public Assessment Report Public Assessment Report Danish 09-03-2022
Patient Information leaflet Patient Information leaflet German 09-03-2022
Public Assessment Report Public Assessment Report German 09-03-2022
Patient Information leaflet Patient Information leaflet Estonian 09-03-2022
Public Assessment Report Public Assessment Report Estonian 09-03-2022
Patient Information leaflet Patient Information leaflet Greek 09-03-2022
Public Assessment Report Public Assessment Report Greek 09-03-2022
Patient Information leaflet Patient Information leaflet English 09-03-2022
Public Assessment Report Public Assessment Report English 09-03-2022
Patient Information leaflet Patient Information leaflet French 09-03-2022
Public Assessment Report Public Assessment Report French 09-03-2022
Patient Information leaflet Patient Information leaflet Italian 09-03-2022
Public Assessment Report Public Assessment Report Italian 09-03-2022
Patient Information leaflet Patient Information leaflet Latvian 09-03-2022
Public Assessment Report Public Assessment Report Latvian 09-03-2022
Patient Information leaflet Patient Information leaflet Lithuanian 09-03-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 09-03-2022
Public Assessment Report Public Assessment Report Lithuanian 09-03-2022
Patient Information leaflet Patient Information leaflet Hungarian 09-03-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 09-03-2022
Public Assessment Report Public Assessment Report Hungarian 09-03-2022
Patient Information leaflet Patient Information leaflet Maltese 09-03-2022
Public Assessment Report Public Assessment Report Maltese 09-03-2022
Patient Information leaflet Patient Information leaflet Dutch 09-03-2022
Public Assessment Report Public Assessment Report Dutch 09-03-2022
Patient Information leaflet Patient Information leaflet Polish 09-03-2022
Public Assessment Report Public Assessment Report Polish 09-03-2022
Patient Information leaflet Patient Information leaflet Portuguese 09-03-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 09-03-2022
Public Assessment Report Public Assessment Report Portuguese 09-03-2022
Patient Information leaflet Patient Information leaflet Romanian 09-03-2022
Public Assessment Report Public Assessment Report Romanian 09-03-2022
Patient Information leaflet Patient Information leaflet Slovak 09-03-2022
Public Assessment Report Public Assessment Report Slovak 09-03-2022
Patient Information leaflet Patient Information leaflet Slovenian 09-03-2022
Summary of Product characteristics Summary of Product characteristics Slovenian 09-03-2022
Public Assessment Report Public Assessment Report Slovenian 09-03-2022
Patient Information leaflet Patient Information leaflet Finnish 09-03-2022
Public Assessment Report Public Assessment Report Finnish 09-03-2022
Patient Information leaflet Patient Information leaflet Swedish 09-03-2022
Public Assessment Report Public Assessment Report Swedish 09-03-2022
Patient Information leaflet Patient Information leaflet Norwegian 09-03-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 09-03-2022
Patient Information leaflet Patient Information leaflet Croatian 09-03-2022
Public Assessment Report Public Assessment Report Croatian 09-03-2022

Search alerts related to this product

View documents history